UH Cancer Center, Queen’s Health partner on Hawai‘i’s first on-campus cancer clinical center

Rucaparib maintenance therapy demonstrates PFS benefit for HRD-negative and HRD-positive ovarian cancer

First-line rucaparib maintenance treatment provided a progression-free survival benefit vs placebo in newly diagnosed, advanced, high-grade ovarian cancer after front-line platinum-based chemotherapy.

June 27, 2025

Vol.51 No.25

Cancer Policy

FDA halts new clinical trials that export Americans’ cells to foreign labs in hostile countries

FDA has announced that the agency will begin immediately reviewing all new clinical trials that include shipping American citizens’ living cells to “China and other hostile countries for genetic engineering and subsequent infusion” back into American patients.

June 20, 2025

Vol.51 No.24

By Claire Marie Porter

In Brief

Peter Voorhees named associate director of clinical research at Wake Forest

Peter Voorhees was promoted to associate director of clinical research and will oversee clinical research for Atrium Health Wake Forest Baptist Comprehensive Cancer Center, as well as all processes related to clinical protocol and data management and protocol review and monitoring system.

June 20, 2025

Vol.51 No.24

In Brief

Samra Turajlić appointed director of Cancer Research UK Manchester Institute

Samra Turajlić was appointed the director of the Cancer Research UK Manchester Institute.

June 20, 2025

Vol.51 No.24

Clinical Roundup

Study of retifanlimab in squamous cell carcinoma meets primary endpoint of PFS

Primary results from the phase III POD1UM-303/InterAACT 2 trial of retifanlimab (Zynyz), a humanized monoclonal antibody targeting programmed death receptor-1, in combination with carboplatin and paclitaxel (platinum-based chemotherapy) in adult patients with inoperable locally recurrent or metastatic squamous cell carcinoma of the anal cancer who have not been previously treated with systemic chemotherapy, were published in The Lancet.

June 20, 2025

Vol.51 No.24

Drugs & Targets

FDA approves Zusduri for intravesical solution in recurrent LG-IR-NMIBC

FDA has approved Zusduri as the first and only FDA-approved medication for adults with recurrent low-grade intermediate-risk non-muscle invasive bladder cancer.

June 20, 2025

Vol.51 No.24

UH Cancer Center, Queen’s Health partner on Hawai‘i’s first on-campus cancer clinical center

YOU MAY BE INTERESTED IN

Rucaparib maintenance therapy demonstrates PFS benefit for HRD-negative and HRD-positive ovarian cancer

FDA halts new clinical trials that export Americans’ cells to foreign labs in hostile countries

Peter Voorhees named associate director of clinical research at Wake Forest

Samra Turajlić appointed director of Cancer Research UK Manchester Institute

Study of retifanlimab in squamous cell carcinoma meets primary endpoint of PFS

FDA approves Zusduri for intravesical solution in recurrent LG-IR-NMIBC

Renew today!

Subscriber content

Never miss an issue!

Login